Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 14, 2009

View Archived Issues

In vivo data suggest high drug load delivery of 259C/MBX-500 via emulsion formulation

Antibacterial activity of razupenem further detailed in vitro and in vivo

Data show Afresa efficacy in diabetes with no significant effects on lung function

Dalcetrapib effective and well tolerated in diabetes and metabolic syndrome patients

Recent clinical data show advantages of alogliptin plus pioglitazone combination

Liraglutide shows advantages over glimepiride in LEAD-2 type 2 diabetes study

Repeat-dosing toxicology studies of ATL-1103 are completed in mice and primates

The FDA has granted marketing approval to CSL Behring's Berinert in HAE

EMEA grants orphan drug designation to AMT-080 for Duchenne dystrophy

Debiopharm completes European decentralized registration procedure for Decapeptyl

FDA grants orphan drug designation to MolMed's NGR-hTNF in liver cancer

ActoGeniX completes phase IIa trial of AG-011 in moderate ulcerative colitis

BioAlliance granted approval in France to initiate phase I clinical trial of fentanyl

ImaginAb signs licensing agreement for BZL Biologics' PSMA technology

Provectus completes patient accrual and initial treatment in phase II trial of PH-10

Schering-Plough initiates proof-of-concept phase I trial of SCH-900795 influenza vaccine

Dilafor completes phase I clinical study of DF-02 for the treatment of severe malaria

MSDC receives grant to study PPAR-sparing insulin sensitizers in AD

Re-engineered ABY-025 shows specific HER2 binding, favorable biodistribution

Sulindac exhibits protection against myocardial ischemic damage in preclinical study

CGI Pharmaceuticals reports Syk inhibitors for the treatment of asthma

Novel tubulin polymerization inhibitors discovered by Pierre Fabre

Novel dopamine D2 receptor partial agonists in development at AstraZeneca

Alkermes reports results from clinical trials of ALKS-33

Metabolex reports results from two phase I clinical trials of MBX-2982

FDA and EMEA grant orphan drug status to Antisoma's AS-1411 in AML

Onyx to acquire Proteolix, along with carfilzomib for multiple myeloma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...